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INTRODUCTION 
From the time of the first, attemots at cancer chemotherapy with 
nitrogen mustards introduced at Yale by Gilman in 1948 (13), many classes 
of compounds have been developed. Among these are the alkylating agents 
and antimetabolites as recently reviewed by Boy1 and (5), the corticosteroids 
and antibiotics as reviewed by Arkin (2), and the folic arid antagonists, 
reviewed by Jaenicke (25). Despite the multiplicity of agents, only one 
drug, methotrexate, has resulted in five year regressions in only one tumor, 
choriocarcinoma in women (5). All of these authors have further referred 
to the toxicity, potentially fatal, of most of the drugs at the doses that 
must be used for tumor regression. Recently interest has turned toward toe 
use of the halogenated pyrimidines, summarized by Welch, Calabresi and 
Prusoff 1963 (39). 
Within the last decade, the technical, side of radiotherapy has rapid¬ 
ly progressed with the addition of greatly improved supravoltage x-ray 
machines generating 1 to 70 million electron volts and tel.etherapy 
easily maintained cobalt 60 sources, plus the addition of isotope therapy 
(29). However, radiotherapy still is not a totally satisfying means of 
tumor therapy. Our attention has been drawn to the possibility of augment¬ 
ing the effectiveness of radiation on the cell or sensitizing the cel1 to 
radiation by combination of x-ray with various chemical agents in the cone 
of increasing the therapeutic effect while holding toxic effects within 
acceptible levels. Furthermore, it has been our purpose to attempt to dis¬ 





Bane et al (4) has reviewed the field of combination therapy divi¬ 
ding the various chemical agents used, into carcinostatic agents, agents 
that increase susceptibility to x-ray without an effect of their own (sen¬ 
sitizers), and secondary radiators or carriers. Among the carcinostatic 
agents discussed are the alkylating agents, urethane and the purine ana 1c'rites 
while Oo, various dyes, and synkavit are mentioned among the sensitizers'. 
Spengler et al (35) used L-triiodothyronine in combination with 450f‘r x-ray 
on mouse breast tumors but noted no significant difference between combined 
therapy and x-ray alone. After an initial tissue edema, tumors did regress 
in size, but there was also an increase in the mortality from irradiation 
used in combination with the drug. Work has also been done using Vasodilator 
(acetylcholine and tolazoline) with 2600r x-ray, but only suggestive rises in 
the expected oxygen effect have been shown (27), Attempts have been made by 
Goldin and Mantel (15) to obtain therapeutic synergism (an effect greater 
than would he expected by adding the results of each therapy alone) by using 
two drugs together without x-ray. In most cases, toxicity as well as ecf*"-c«~ . 
ness was reduced, but some ’enhanced effectiveness5 was obtained with cii.ro- 
vorura factor given in advance of aminopterin, Leucutia (30^ obtained mai .■ 
and long palliative effects with colloidal lead orthophosphate and x-ray m 
bone neoplasms and with neostibosan and X-ray in multiple myeloma. 
Kligerman (26) has evaluated some of the various chemicals that have 
been used in combination with x-ray and the evidence that exists for radio¬ 
sensitization. Included are the original studies of the Yale group on 
5-Iododeoxyuridine■ Presently great interest is centered in the halogenafced 
pyrimidine analogues. Szybalski (36) has demonstrated, with diugs sue.1 ’a 
ve 

S~chl.orqdeoxyu.ridine, 5-browodeoxyuridine, and 5-Iododeoxyuridine, that 
there is ^Corporation of these synthetic chemicals into strands of 
Enough time must be allowed so that the BNA molecules can incorporate the 
drugs. Originally it was believed that substitution was needed in at least 
two strands to obtain a therapeutic effect. However, sensitisation to j 
lesser degree does occur with single strand substitution. Thus some feel 
that, it might be best to give the drug over several days to a growing tumos 
batski believes the WA seems to be sensitized because of an intensive 
increase in radiation lability and a partial or complete loss of the Dv-.\ 
molecules’ ability to undergo enzymatic or non-enrymat.ic repair. Bag'sbav f"v 
used 5-FU in vitro (with Hela cells) and demonstrated that 5--H1 a’one nr■u • 
enhanced the growth of the Hela cells at low concentration, but, if given fmw 
hours prior to 10-600r x-ray, a greater decrease in the number of cells we 
observed, than with x-ray alone, A 1.4 greater effect of rad nation by the 
addition of 5-FU was observed (3), 
Clinically, great interest has turned to 5-Fluorouracil, a pyrimidine 
analogue synthesized by Reidelberger and co-workers (21-24), because of its 
singular success as being one of the few drugs with any effect on ■ n. 
especially carcinomas of the breast, ovary, large bowel, rectum and hepat >mr 
Significant regression, unfortunately, is seen only when the diug 1s use 1 
the toxic level Extensive clinical and laboratory trials- are now in prog-ess 
on the use of 5-FU attempting to lower its toxicity or maintain it within 
acceptable levels by combination therapy with x-ray, 
The antimetabolite itself 5-Fluorouracil (5-FU) has been found to 
exert its antineoplastic effect by inhibiting the formation of thymidylic 
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d -iecess ir tr the formation of de soxyriboneiiclei< ■ id (1) A : 
acting as an antagonist, to ribonucleic acid (P.V.k) synthesis . 
orotic acid, the precursor compound, is converted to the pyrimidines, 
cytosine, thymine, and uracil.. Heidelberger (211 has shown that 5“FT1 cart 
take the place of uracil in metabolism without losing its- fluoride Ion 
which passes for hydrogen and blocks the position of normal methyl at ion cf 
the uracil, Thus 5-FU can go through normal anabolism to give a fraudulent 
DMA as well as in some way inhibiting its formation. Thymidinedesoxyribo- 
l 
phosphate (TDRP) is known to be formed from Uridinedesoxyribophosphete (UUFF) 
by a methylation reaction catalyzed by thymidylate synthetase in the presence 
of tetrahydrofolic acid, 5-FU is metabolized to form 5 fluoro 2 deoxyuridine 
5 monophosphate which in turn has been discovered to be the substance that 
inhibits thymidylate synthetase activity. This inhibition seems to be the 
crux of the chemotherapeutic action of 5-FU, Combination therapy with 5-t-i 
does not seem to cause any additive inhibition of thymidylate synthetase. 
- Instead, Heidelberger has evidence that the presence of irradiation causes 
a block in the induced formation of thymidine kinase before this enzyme has 
a chance to rise as it would in normal conditions. This may play some rote 
in sensitization but exactly bow combination therapy exerts its effect i s 
known. Heidelberger and his co-workers have thoroughly investigated t. e 
action of 5-FU illustrating the decreased inhibition of thymidylate synthetase 
in resistant tumors, the requirement of ATP for the action of 5-Fb . and the 
failure of formate to he incorporated in TINA thymine in the presenc e o- 
5 fluoro 2 deoxyuridine 5 monophosphate 
Experiments with 5-FU alone have demonstrated variable effects on a 
wide variety of neoplasms. Heidelberger (221 has obtained the foil c'. i -•-> 
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E0771 Mammary adenocarcinoma 
F1exner-JobXina carcinome 
Walker 256 Carcinoma 
Ehrlich Ascites Carcinoma 
L1210 Leukemia 










Increased survival time 
Increased survival time 
Increased survival time 
Vermund et al (37) investigated the use of combination therapy on 
transplanted adenocarcinomas in mice using 300r daily for 5 days amounting 
to a total of 5. lOOr of x-ray in 23 days and 35 mg/lcg of 5-FU for 5 days 
then 17 5 mg/kg twice weekly for two weeks. This regimen of therapy gave 
an average survival time in Swiss albino mice with sarcoma of 73.9 and 62 ° 
days as against an average survival of 25.6 and 18,8 days in the centre1 
mice. Eight out of 19 mice showed complete regression of tumor with 5-FU 
and x-ray whereas x-ray alone merely inhibited tumor growth and caused no 
regression. Z mice with an adenocarcinoma seemed to respond to combination 
5-FU and x-ray therapy having an average survival of 72.8 and 71.2 days as 
compared with 42 and 53.8 days in the control groups. Only one of the tumor 
disappeared completely. These results are difficult to evaluate in terms 
of the effect on humans. The resxilts in far advanced malignancy have, for 
the greater part, been inconclusive. Generally speaking, 5-FU given alone 
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mice fails to cause regression yet it: will, in human carcinomas • i the 
breast, colon and ovary (37). The validity of comparing the results ob¬ 
tained with spontaneous and transplanted tumors in mice to human tumors 
are unknown. Also, the response of mouse tumors to combination therapy 
has been noted by Heidelberger (22) to vary but, in general, he has noticed 
o 
an appreciable tumor inhibiting effect especially with 5-FU and x-ray in 
combination on sarcoma 180 and 775 mammary adenocarcinoma where there is pv< !e 
of potentiation (22). 
In humans, Gold and Hall (14),Winston et al (40), and Olson and 
Greene (31), have found that 5-FU alone has caused regression in 19.6% of all 
carcinomas treated with the longest remissions noted in cancers of the breast 
and uterus (50.8% experiencing some relief). Hall et als (17) have found 
that 5-FU is most effective in cancers of the breast, ovary, large intestine, 
rectum and in hepatomas. 
The conventional doses of 5-FU in therapy are 15 mg/kg/day for 5 days 
by rapid IV injection (not to exceed 1 gm per day) and 7.5 mg/kg every other 
day until toxicity appears. Although possessing a definite anti-tumor effect, 
5-FU has a very narrow therapeutic index (Olson et al (31) noting 184 rata! 
toxicity among their patients). The most common toxicities consist of stoma:. 
(40% Freuge'rson & Humphrey in Olson et al (31); nausea, vomiting, or diarrhea 
(87%)■ leukopenia (70%), anemia and ulceration of the gastro-intestinal tract 
(31). Delayed effects include alopecia and increased pigmentation of the 
skin (16). A sudden agranulocytosis can occur after cessation of the treat¬ 
ment (Olson et al) (31) and Winston et al (40) noted a high frequency of 
euphoria when using 5-FU. Recent work has been aimed at methods of allevi-t i 




: r: r 
( 
in toxieit} has been obtained by simply -prolongi xg th« Imi is ratio time 
although the incidence of sclerosing phlebitis then increases (12). More 
recently, the concoromitant use of 5-FU and x-ray therapy has been. invesLigac- 
In Inoperable tumors of humans, Hall et als (17) have found that 
pushed to toxic doses, and 2000 - 2250r x-ray over a period of several wee! 
, o 
does produce additive or potentiating effects in carcinomas of the breast, 
ovary, large bowel, rectum and hepatomas.. Tumors of the lungs, stomach, 
pancreas and kidney did not seem to respond (17), Yet, despite all 
toxicities such•as stomatitis, diarrhea, suppression of hematopoesis, and 
ulceration of the G.I. tract still occurred. Frank et al (12) has been able 
to alleviate some of the toxicity of 5-FU by prolonging its administration 
time to 8 hours of I.V. infusion. Using this prolonged administration of th" 
conventional doses of 5-FU in combination with 1900~7000r x-ray, they obta“nr 
regression of tumor size in 50% of their patients with assorted types of in¬ 
operable carcinomas (12). Hall and Good (16) also investigating treatment 
of advanced neoplastic disease with 5-FU and irradiation, found that the be t 
therapeutic effects were obtained when the toxicities of 5-FU first appeared 
They noticed that with combination therapy, gastrointestinal ulcers and 
suppression of hematopoesis occurred along with the desired antineoplasti 
results in carcinomas of the head and neck, ovary, and breast. 
In 1960, Foye et als (11) tried using 5-FU in non-toxic, doses 
(15- mg/kg for 5 days followed by 2.5 mg/kg tv; ice weekly) with 2000r tote’ 
x-ray and obtained significant regression of epidermoid carcinomas of t' e 
lung and larynx, which normally do not respond to the drug alone. Crews (8‘; 
using the conventional toxic doses of 5-FU (15 mg 'kg for 5 days, 7,5 m" 'kg 
every other day til 1 toxicity) with ? Mev radiation on 33 patients with 

advanced solid tumors.i noted 'vomiting, diarrhea?, stomatitis and leuk pent, 
in a majority. of the patients followed Vascular co! lapse and -dopcr’a 
vas noticed in 507 while dermatitis and phlebitis were a1--., < .irnmon occurrence 
(R), Eleven patients received good palliation with a decrease i.n tumor 
relief of pain, and weight gain of a 4-6 month duration (8). Ten patients 
o 
had poor palliation with only temporary regression of 2-3 months followed 
by. a regrowth or•relapse (8). Finally, 9 patients showed no response what¬ 
soever (8). Crews, with the exception of the results on G.I. tumors, noted 
no indication for a potentiating effect with combination therapy, on solid 
tumors (8).. Somewhat unusual results were found by Allaire efc al (1) when 
they reported that objective improvement was noted with combined therapy 
(conventional doses of 5-FU and 2000r x-ray over 2-4 weeks) on tumors of the 
pancreas, stomach and bronchus. They obtained only promising results on 
neoplasms of the gastrointestinal tract and lungs. Cornell et al (7) found 
that combination of 5-FIT and x-ray only caused arrested growth of tumors wit1 
I 
a stable course followed by further growth instead of regression. On the 
other hand, Faye et -al.s (101 claim that concomitant use of 5-FIT (conventional 
dose) and local irradiation (2000r) gave a greater degree and higher incidence 
of tumor regression than is obtainable with either mode of therapy alone. 
The effects noted also exceed those that would be expected on the basis or 
additivitv alone (10). Foye (10) thus concludes that he has observed a 
synergistive effect with combined therapy. Recently, however, von Fssen, 
Kligerman, and Calabresi (35) in. a controlled study in humans, failed to 
demonstrate a significant alteration in the response of multiple metastatic 
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Tt i« obvious that a wide difference of opinion exists to the 
effectiveness of 5-FU and x-ray used in combination. In addition, the 
question has recently been raised in any combination drug and radiotherapy 
as to whether an optimum time-sequence for administration of the treatment 
modes exist (28), The present study was undertaken to find an optimum 
time-sequence of administration of 5-FU and x-ray and in the process to 
evaluate the effectiveness of combination therapy. ' 
■I! 
:" I 
MATERIAL AND METHOD? 
A mammary adenocarcinoma which arose spontaneously in our C3I? colony 
and had been subcultured for many generations was transplanted into the 
D 
left thigh of 215 mice. 60% of these mice were C3H/CGRI, and the remainder 
C3H/JAX. All but 42 were males. In general, the mice were 4-6 months old 
at. the start of the experiment. 
A mouse carrying the tumor was sacrificed without anesthesia, the 
tumor being removed and minced under saline. Fifty C3H mice were then 
innoculated with minced tumor by a size 13 trocar in the left'thigh. About 
10-1? days after transplantation, 42 of the 50 mice whose tumors were suit.(bl- 
measurable were selected. Only tumors of fairly uniform size (4-0 mm average 
diameter) were used in order to reduce bias. These 42 mice were then assigned 
randomly to 7 groups of about 6 animals each. 
X-ray treatment, was carried out in X/4n thick boxes with the animal1: 
left leg held out by a string and placed directly under the 1.5 cm. cone. No 
anesthesia was used. 
With day #0 as the day of initiation of treatnu 
measured on the following fixed days: #1, 2, 3, 4, 5, 6, 7, 9, 11, 13, 15, 
19, 26, 33, 40. Tumor volume was calculated by multiplying the three dimen¬ 
sions together, as measured by a standard caliper, and multiplying this 
figure by .524. Most of the treated mice and all of the untreated ones 
died of metatasis within this 40 day observation period. For the duration 
of the period of observation,the various groups were assigned randomly to 
several cages to avoid the cage effect as described by Raventos (32). In 
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this way, distortion of the final results by events within the population 
of any one cage was reduced. 
Therapy, as mentioned, consisted of both x-irradiation and 5-Fluor- 
ouracii. One intraperitoneal injection of 125 mg/kg of 5-Fluorouracil (an 
as determined by preliminary dose-response studies but an LD.q in this expe 
iment) was used throughout. This was an effective dose with the highest 
acceptable mortality rate. The x-ray dose chosen (based on prior experimer 
was one local treatment of SOOOr, an EDg for long-term regression of local 
These doses were selected to insure that any additive or enhanced efforts 
would not be masked. The machine was set at 250Rv, 15 mg, with a 2 mm AL 
Filter. .The cone length was 3 cm and the distance from the cone to the tar 
get was negligible. Victoreen readings of the lOOOr chamber timed for one 
minute of machine output averaged about 900r/min, corrected. 
The treatment groups received the following reg?Lmens: 
Group I « received local x-ray dose of 5000r. 
Group IT. - received, an intra-peritoneal injection of 5-FU, 
dose - 125 mg/kg (LDiq). 
Group III - received the injection of 5-FU and If minutes 
later received SOOOr x-ray. 
Group IV - received the injection of 5-FU and 3 hours later 
received 5000r x-ray. 
Group V - received the injection of 5-FU and 24 hours later 
received SOOOr x-ray. 
Croup VI - received SOOOr x-ray and 24 hours later received 
the injection of 5-FU. 
Group VII - served as the control and received no treatment. 
■ - • - 
Each lot of about 42 mice was treated as outlined above and con¬ 
sidered ss a separate experiment m run. The total study was composed 
of 5 such identical experiments each containing the same 7 treatment 
groups (total of 215 mice) outlined above so as to help avoid chance 
events and spurious results distorting the final, results. In order to 
minimize, the influence of host factors, only the rate of decree/..-- in the 
size of tumors was used in comparing the several treatment schedules in 
a model system, little emphasis being placed or. cure or survival rates. 
The latter are recorded, however. 

RESULTS 
Emphasis is placed on the progression of tumor volume:-, 
various modesiof therapy. Other parameters followed included 
following the 
*curc1 , death. 
and survival rates. 
The variability of response of the individual mice was so great 
differences within each group were greater than, the differences between th • 
groups. The mice which died early were considered dead ol toxicity. 
. 
groups for each run and the corresponding groups from each run were 
together for comparison. In figure 1, the tumor sizes of the groups rc-ceiv 
x-ray alone (Group I) are plotted, the number of surviving mice being indi¬ 
cated by a number above each point on the graph. It should be noted at th: 
point that Run 5 was the only run employing female C?H mice. Sex. however4 
was not a factor affecting the results. The groups with 5-FIT alone (Croup II) 
(figure 2), with the exception of one mouse, show ho response in an]. 
the drug alone. Giving the drug 15 minutes prior to x-ray therapy (Group HI' 
(see figure 3) seems to have caused an inhibition of tumor growths after 3- '• 
days lasting until about the fifteenth day. At this point, growth of the 
tumor invariably resumed. The results of the groups receiving 5-FU three 
hours ptior to x-ray (Group IV) (Sec figure 4) are similar to Group HI. 
There is inhibition in tumor growth and even some regression of tumor size 
followed by regrowth of the tumor in greater than 75% of the remaining mice. 
The groups receiving 5-FU 24 hours prior to x-ray (Group V) (See figure 5 
resemble Group IV.with the exception of the existence of a few create ' ?.xtrem 
-13- 

in tumor si.se. In the grouns receiving x-ray V\ hours prior to 5-FIT (Group VI) 
(See figure 6) , there are again quite variable but not significantly dif fe’-en: 
results from those of the other combined treatment groups. The tumors of the 
controls (Group VII) (figure 7) grow quite rapidly as is expected. One mouse 
in Run 3 had an unusually long survival, dying only after a very large tumor 
had grown. 
For further consolidation of the results, all of the tumor volumes in 
each treatment group, were averaged together and plotted as one curve (figure s). 
'he general trend.for each group is clearly illustrated, but one must be mindful 
that the fewer the surviving mice, the less representative are the average tumor 
sizes. Standard errors of the mean were calculated at each day of observation 
and are represented on. separate graphs for each treatment group (figures 9-15). 
The standard errors, based only on the surviving animals, became unreliable after 
day ip because of attenuation of the colony dxxe to tumor deaths. The standard 
error.for each group at day 19 is recorded on the composite graph (figure 8). 
The number of survivors in each treatment group at fixed days after treatment 
is shown in Table I. 
Up to the 19th day, there is no statistically significant difference 
between the group receiving x-ray alone (Group I) and any of the combination 
therapy groups (Groups III-VI). After the 1.9th day-, a general increase, .in 
average tumor volume, is noted in all of the combination therapy groups, where¬ 
as a slight decrease is seen in the group with x-ray alone (Group I), This 
"•ate difference cannot be subjected to statistical analysis due to the sma11 
number of survivors. Likewise, there is little difference between the con¬ 
trol group (Group VII) and the group receiving chemotherapy alone (Group Tf'. 
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continuously increased in size after chemotherapy, alone until the 19th day 
and then began to regress until the death of the mouse. Therefore, this 
point should be disregarded. This is the. only incidence of tumor regression 
in either of these 2 groups (IX or VII). Both of these groups, however, 
differ significantly from all those receiving x-ray. It is noteworthy that 
in no group was the final average tumor volume smaller than the starting 
average tumor volumes, although the group with x-ray alone (Group I) approached 
this. (Figures 9-15 show the average tumor sizes of each group separately 
with the standard errors included). 
Since we were working with transplanted tumors, the most meaningful 
data is represented by the regression and growth rates. (Host factors in¬ 
fluence tumor ’cures"). However, Tables 2M and 2b are included to show de¬ 
tailed data on permanent regression of the primary tumor md complete regression 
followed by recurrence. The causes of death following treatment are listed in 
Tables 3a and 3b, Most mice died of metastases from the implanted tumor in¬ 
cluding those that obtained temporary "cures’ at the original tumor-site 
(tumor no longer palpable or observable). The mice listed as "permanent 
regression" had no evidence of original tumor or metastasis when sacrificed 
4-5 months after the 40 day observation period. The x-ray dose (5000r) 
given to Group I gave a temporary local cure of.40% (ED^q for regression 
of local tumor followed by recurrence). This same degree of effectiveness was not 
noted in any of the other groups receiving 5-FU in addition to the same x-ray 
dose. In fact, the percentage of temporary complete regression of local tumor 
ranged from a low of only 25% in one of the combination groups to a high of 
36% in one of the other combination groups, the difference between groups not 
being significant. An EFg for permanent regression of local tumor was obtained 
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with 5000r„ That is to say, permanent cures occurred in 13 or 8% of all 
the mice. No cures occurred in the mice treated with drug alone.. The rest 
of the mice, i.e. those that were not cured or did not die. of metastases, 
(the large-majority of which were in the combined therapy groups) died earl-' 
in the course of the experiment from a side reaction of therapy. The doses 
of 5-FU given by itself was a LD.Q under experimental conditions as indicated 
by the toxicity found in Group II (5-FU alone). The other groups receiving 
5-FU (the combined therapy groups) had a slightly higher incidence of toxicity. 
In fact, there was an average of 23-30% fatal, toxic it ies with combined therapy 
as against no such cases with x-ray alone. The miscellaneous causes of death 
were few and included events such as injection damage and infections that were 




The above results revealed that not only did the timing of admin- 
istration of therapy fail to play an important role, but also no combina¬ 
tion regimen seemed to give greater antineoplastic effect than was noted 
with x-ray therapy alone. The lack of potentiation of radiation by 5-FU 
in these experiments correlate with the .clinical report of von Essen 
co-workers (38). This study, using x-ray alone, 5-FU alone, and combination 
therapy on multiple metastatic tumors within individual patients, failed 
to demonstrate a significant alteration of response of tumor to irradia¬ 
tion by the addition of 5-FU. 
There was a wide range in degree of effectiveness among the mice 
responding to therapy. Some mice did not respond at all to a therapy 
schedule that in other mice would cause a disappearance of the original 
tumor. Treatment in some was sufficient only to cause transitory inhibition 
in tumor growth followed by resumption of the previous growth rate whereas 
in others, regression in size or even complete disappearance was fol 
by regrowth. In each case, it appeared as though the administered therapy 
regimen was only partially carcinolytic, the remaining viable cells account¬ 
ing for the following regrowth. In some cases, these remaining cancer cell., 
did not apparently have aa opportunity to regrow since fatal metastase^ had 
already taken place. 
There is the possibility that the administration of 5-FU even ?J\ 
hours prior to x-ray was inadequate time for full sensitization. Yet Bagsha 
(3) has reported obtaining enhanced x-ray effects on Hela cells when 5-FU 
was added only 4 hours prior to x-ray. Szybalski (36), on the other hand, 
has noted that the sensitizing effects of purine and pyrimidine analogues in 
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general appear to be greatest approximately 4 days after drug exposure-. 
He, however, has worked mainly with EUDR and IUDR which is incorporated 
into the DNA. In our instance, nonetheless, there was not; even the 
slightest indication of a minimal sensitising effect by the drug in a 2k 
hour period. A possibility exists that, either the drug or the x-ray given- 
first might impede rather than enhance the other’s effect. Both the effect 
of 5-FU and irradiation depend to a large degree on a viable, and rapidly 
growing tumor. Administration of either drug or x-ray first could damage 
the tumor sufficiently so as to diminish the effect of the other treatment 
following thereafter. Other investigators have noted enhanced effects :>n 
mouse tumors with combination therapy. Vermund (37) reported enhanced sur¬ 
vivals with mouse sarcomas and adenocarcinomas. His results, however, ar... 
neither consistent, nor do they meet the criteria for true sensitization 
set forth by Schoeniger et al (34). 
Since no difference in any of the groups with combination therapy was 
found, the lack of an optimum time-sequence of administration is not eurprlMn 
The average tumor volumes of all the mice receiving any of the combined th'n 
regimens remained within one standard error of each other. This cannot b 
to mean that there, is no such optimum, but there was no such indication here. 
Since transplanted tumors have been used, not much reliability is being 
placed on the cures, permanent or temporary, obtained. The effect of var' m 
host factors on transplanted tumors have been known to play an important ro’e 
in determining the effectiveness of cure of a certain mode of therapy. Fur¬ 
thermore, tumors that have been transplanted in one strain for many gene-it r ■ 
seem to become much more amenable to cure. The reasons for this are not ■ 
but these factors are not involved to the same degree in rate of dec re.'.e 1 
tumor size. This 1 utter response is thus a more reli ble indication f t1 

efficacy of the therapy here, tt is interesting, however, that all groups 
in this study, with the exception of the controls and those receiving drug 
alone, had some scattered permanent cures (long-term regression of local 
tumor).. All of the mice with temporary regression of local tumor eventual1;' 
died of metastases as did the vast majority of all mice regardless of treat¬ 
ment group. Only about four revealed no metastases at autopsy and death 
was assumed to be due to the large-sized, original tumor. The metastases 
were in. general, throughout the lymphatic system, especially in the mesenteric 
nodes and adrenal glands. Other causes of death are listed in Table 3. 
The observation that the drug itself had little effect on tumor 
growth is consistent with that of Vermund who also has noted that 5-FU al :>ne 
fails to cause regression in mouse- adenocarcinomas the way it will on human 
cancers of the breast, colon and ovary (37), The dose of the drug which we 
used, an ID,^ as determined in a pilot study, was sufficient to cause a 
197 fatal toxicity under experimental conditions and thus was present in sub¬ 
stantial amounts within the mice treated. This was a dose considered to be 
reasonably effective and one that with the x-ray dose used -/5000 s ^r'/4f) 
for temporary complete regression of local tumor and EP for permanent 
regression of local tumor) would not obscure any additive effect that might 
be found. No deaths from treatment toxicity were noted in the controls or 
the groups receiving x-ray alone (the only groups not receiving 5-FU). 
the fatalities due to treatment were considered drug toxicities, at the most 
being enhanced by irradiation as evidenced by the 23-to 3011 fatal toxic it] 
in the combined therapy groups as opposed to 197 with drug alone. This i- 
-19- 
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not at all an unfamiliar finding. Frank (12) baa cited the lov therapeu?" ‘ 
index of 5-FIT as being a hazard. When used with x-ray therapy he noted a 
higher rate of toxicity, but unlike the results here, he also claimed evidence 
for svnergism of therapeutic effects. (Drug toxiciti.es listed in Table . 
This experiment has been chosen as a model for other possible time- 
sequence studies of combination drug and radiotherapy on tumors. Other t-?re ¬ 
sequences including use of fractionated x-ray doses and other drugs such a- 
5-FUDR and S-ItTUR should be investigated. In addition, it would be profi tabi •- 
to attempt studies to synchronize tumor cells to 5-FU, i..e. halt ceils at 
sensitive part of their cycle with 5-FU, then using fractionated doses of 







The effect of combination 5-FU and radiotherapy was tested by 
measuring the size of a transplanted adenocarcinoma in CgH mice on certain 
fixed days after various sequences of drug and irradiation. Reasonably 
effective doses of 5-FU (125 mg/kg by single I.P. injection, an LD,Q) and 
x-ray (5000r locally, an EDg for permanent regression of local tumors) 
were used. The seven treatment groups were: (I) X-ray alone; (II) drug 
alone; (III) drug 15- rains, prior to x-ray; (IV) drug 3 hours-prior to x-r.-iy 
(V) drug 24 hours prior to x-ray; (VI) x-ray 24 hours prior to drug; (VII) 
no treatment. The total study was divided into five smaller and identi¬ 
cal experiments, with ral.ee being randomly assigned to cages after therapy, 
so as to avoid chance events and spurious findings biasing the total result . 
No significant difference was noted between those, receiving x-ra; 
alone and any other combination of x-ray and drug. Furthermore , there v:rs on I 
slight difference in growth rate between the controls and the mice receiving 
drug alone. Greater variation in response was noted within each group than 
between the groups. 
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